The UAE has become the second country in the world to approve the new lung cancer drug 'Lumakras'.
The Ministry of Health and Prevention (MoHAP) has cleared the registration and use of the drug, which recently received the approval of the US Food and Drug Administration (FDA).
It will help speed up the treatment plan of patients in the UAE and improve their quality of life.
Lumakras, manufactured by Amgen, is prescribed to adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), who have received at least one previous cancer therapy.
It is supplied as film-coated tablets for oral use containing 120 mg of sotorasib.
UAE President joins Etihad Rail journey as Dubai station is inaugurated
UAE President receives Israeli Prime Minister
H.H. Sheikh Mansour set for fraternal visit to Saudi Arabia
UAE to open electronic visa centre in Lebanon
UAE, INTERPOL highlight international coordination to combat crime
UAE President, Turkish Foreign Minister discuss bilateral ties and regional security
Zayed Sustainability Prize unveils 2027 finalists following record global entries
Bookings open for Etihad Rail's Dubai-Abu Dhabi route ahead of launch
UAE launches third National Risk Assessment to tackle financial crime
22 men arrested in Dubai for posing as beggars and scamming people
H.H. Sheikh Mohammed's 'The Letters' arrives in UAE bookstores in October
UAE launches 'Abu Dhabi Call to Action' on environmental crime
H.H. Sheikh Hamdan approves strategy for Dubai Longevity Authority
Sheikh Abdullah attends UAE Youth Dialogue at UN General Assembly
UAE delegation holds economic, health talks at UN General Assembly
UAE signs judicial agreements at UN Crime Congress in Abu Dhabi
UAE workshop discusses priorities for People of Determination strategy
UAE highlights need to protect food supplies from global disruptions
Saif bin Zayed meets justice, interior ministers on crime congress sidelines
UAE highlights efforts to advance international judicial cooperation
